TRHR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It’s the GeneMedi’s summary page for Target/Biomarker Introduction of TRHR. The page also collects GeneMedi’s different modalities and formats products for TRHR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi’s target-insight database-GM ITD database, the TRHR target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes a G protein-coupled receptor for thyrotropin-releasing hormone (TRH). Upon binding to TRH, this receptor activates the inositol phospholipid-calcium-protein kinase C transduction pathway. Mutations in this gene have been associated with generalized thyrotropin-releasing hormone resistance. [provided by RefSeq, Sep 2011]
|
Target ID |
GM-T77796
|
|
Target Name |
TRHR
|
|
Gene ID |
7201
|
|
Gene Official Name |
TRHR
|
|
Gene Alias |
TRH-R
|
|
Protein Sub-location |
Transmembrane Protein
|
|
Category |
Therapeutics Target
|
Anti-TRFR/ TRHR/ TRH-R antibody for FACS & in-vivo assay| GMab
Pre-made anti-TRHR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-TRHR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Warning: Undefined array key "category" in /www/wwwroot/genemedi_com0630/wp-content/plugins/wc-product-table-pro/pro/functions.php on line 2278
